Mednet Logo
CommunityRadiation Oncology

Can I treat breast nodal volumes with hypofractionation?

With the recently reported START (A and B) trial data from the UK, in which patients were allowed to receive hypfractionated doses to nodal regions, is it acceptable practice to treat supraclav/axilla regions with hypofractionation?
5 Answers
Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · University of Colorado School of Medicine
Answered on · Updated on

Yes. Published randomized trials have treated/reported 2,000 patients with doses of >2 Gy in hypofractionation vs standard fractionation trials with treatment to the axilla. Trials include Start A/B (513 patients), the old trial by Ragaz et al., PMID 15657341 (318 patients, hypox 37.5 Gy in 15 fx), ...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · Northwestern University
Answered on

The above discussion is wonderful. I'd like to add a bit by looking to the future. I am aware of 7 active RCTs evaluating the safety and efficacy of moderate hypofractionation and 2.5 RCTs evaluating extreme hypofractionation in RNI. Ultimately, we will have a large dataset from diverse countries to...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · Memorial Sloan Kettering Cancer Center
Answered on

At our institution we are running two sister trials of hypofractionation for intact breast and PMRT patients, in which we allow nodal RT with the same shortened schedule. I get a lot of questions on this, specifically with reference to our rationale/consideration of brachial plexopathy toxicity. Whe...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · University of Colorado School of Medicine
Answered on · Updated on

Adding a meta-analysis addressing this issue to some degree:

Liu et al., PMID 31952507.

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Radiation Oncology · Cancer Center of Hawaii
Answered on

I would personally caution the use of hypofractionation for nodal volumes due to the late risk of brachial plexopathy and would suggest that even 5 years of follow-up does not allow for adequate time to assess the risk of nerve damage.

Khan et al., PMID 28900318

Join for free or sign in to see the full answer